<DOC>
	<DOCNO>NCT00920582</DOCNO>
	<brief_summary>The primary purpose study determine whether teplizumab ( MGA031 ) infusion lead great reduction insulin requirement conjunction near normal blood sugar control compare placebo patient recently diagnose type 1 diabetes .</brief_summary>
	<brief_title>Protege Encore Study- Clinical Trial Teplizumab ( MGA031 ) Children Adults With Recent-Onset Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Subjects 835 year old 2 . Body weight &gt; 36 Kg 3 . Diagnosis diabetes mellitus accord American Diabetes Association ( ADA ) criteria 4 . Randomization Study Day 0 within 12 week first visit physician symptom sign diabetes 5 . Requires insulin T1DM require insulin time diagnosis administration study drug 6 . Detectable fasting stimulate Cpeptide level ( low limit reportable range assay ) screen 7 . Diagnosis T1DM evidence one positive result test follow antibody screen : Isletcell autoantibodies 512 ( ICA512 ) /islet antigen2 ( IA2 ) , Glutamic acid decarboxylase ( GAD ) autoantibody , Insulin autoantibody ( subject insulin 2 week , ICA512/IA2 GAD must positive ) . 1 . Prior administration monoclonal antibody—within 1 year randomization 2 . Participation type therapeutic drug vaccine clinical trial within last 12 week randomization Study Day 0 3 . Any medical condition , opinion investigator , would interfere safe completion trial 4 . Pregnant female lactate female intend provide breast milk baby study 5 . Current therapy GLP1 receptor agonist ( e.g. , exenatide pramlintide ) , agent might stimulate pancreatic beta cell regeneration insulin secretion 6 . Current treatment oral antidiabetic agent 7 . Evidence active latent tuberculosis 8 . Vaccination live virus organism within 8 week randomization continue Week 52 study . Influenza vaccination kill virus , include booster vaccination , within 4 week dose cycle . Vaccination antigens kill organism within 8 week dose cycle 9 . Any infectious mononucleosislike illness within 6 month randomization</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Teplizumab</keyword>
	<keyword>Protege</keyword>
	<keyword>Protege Encore</keyword>
	<keyword>MGA031</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Type 1 Diabetes Mellitus</keyword>
	<keyword>T1DM</keyword>
	<keyword>MacroGenics</keyword>
	<keyword>Recent Onset Diabetes</keyword>
	<keyword>hOKT3γ1 ( Ala-Ala )</keyword>
	<keyword>Encore</keyword>
</DOC>